Global targeted antibiotics market was valued at US$ 19915.11 in 2018 and is expected to reach US$ 21031.51 million by 2029, growing at an estimated rate of 4.4% over the next eight years. Antibiotic is an antimicrobial agent that battles bacterial infections, and sometimes protozoan infections. These are also used to treat many diseases such as strep throat, infections of the urinary tract, infections of the sinus, pneumonia, infections of the skin, infections of the ears and others. There are many ways to classify antibiotics but the most general classification is based on their activity range, chemical structures and mode of action. The market for antibiotic-class beta-lactam and beta-lactamase inhibitors is currently high among healthcare providers. Since the days of leeches and humors, antibiotics have become more and more individualized, but in the last 15 years, an influx of patient data in the form of genetic information and electronic health records (EHRs) has sharpened the physician's view of the individual patient - and of therapies tailored to their specific needs. Such targeted care is referred to as targeted antibiotics - tailoring treatment to a specific patient i.e. designing a medical treatment based on diagnosis, clinical condition, history of patients, physiology of the body and other patient and disease-related factors. Often called precision medicine, stratified medicine or P4 medicine is targeted antibiotics. Diagnostic screening is often done in targeted antibiotics to determine appropriate and effective therapies based on the genetic content of the patient, or other molecular or cellular analysis. Targeted antibiotics have the best response and highest safety margin to ensure enhanced patient care by allowing every patient to attain earlier diagnosis, risk assessment, and best treatment. Additionally, targeted antibiotics market offers opportunities to improve health care by lowering overall treatment costs.

Access Full Report @ https://www.absolutemarketsinsights.com/reports/Targeted-Antibiotics-Market-2019-2027-499

The report provides both, qualitative and quantitative research of targeted antibiotics market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.

Major players operating in the global targeted antibiotics market are Abbott Laboratories, Merck & Co., Inc., AstraZeneca, Pfizer, Inc., GlaxoSmithKline plc., Novartis AG, Amgen, Inc., Bayer AG, Mylan N.V., Eli Lilly and Company, Bristol Myers Squibb Co., Daiichi Sankyo Company, Ltd., Biogen, Inc., Johnson & Johnson Services, Inc., F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Inc., Novo Nordisk A/S, and Sanofi Genzyme.

Targeted Antibiotics Market:

By Action Mechanism

  • Protein
  • DNA
  • RNA
  • Cell Wall Synthesis Inhibitors

By Drug Class

  • Penicillin
  • Cephalosporins
  • Fluoroquinolones

By Geography

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Contact Us:
Company: Absolute Markets Insights
Email id: sales@absolutemarketsinsights.com
Phone: +91-740-024-2424
Contact Name: Shreyas Tanna
Website: https://www.absolutemarketsinsights.com